<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02715466</url>
  </required_header>
  <id_info>
    <org_study_id>HC-G-H-1209</org_study_id>
    <nct_id>NCT02715466</nct_id>
  </id_info>
  <brief_title>Gelatin in ICU and Sepsis</brief_title>
  <acronym>GENIUS</acronym>
  <official_title>Prospective, Controlled, Double-Blind, Randomized Multicentric Study On The Efficacy And Safety Of An Early Target Controlled Plasma Volume Replacement Therapy With A Balanced Gelatine Solution vs A Balanced Electrolyte Solution In Patients With Severe Sepsis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>B. Braun Melsungen AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>B. Braun Melsungen AG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective, double-blind randomized controlled trial evaluates the differences in terms&#xD;
      of efficacy and safety of gelatin based resuscitation as compared to crystalloid based&#xD;
      resuscitation in two parallel groups of patients with severe sepsis / septic shock.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time until first/initial hemodynamic stabilization</measure>
    <time_frame>48 hours after treatment start</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of stay (LOS) in the intensive care unit (ICU)</measure>
    <time_frame>Intensive care unit (ICU) discharge or day 28</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">608</enrollment>
  <condition>Hypovolemia</condition>
  <arm_group>
    <arm_group_label>Gelatine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Balanced gelatine solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Electrolyte</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Balanced electrolyte solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Balanced gelatine solution</intervention_name>
    <description>Gelaspan combined with Sterofundin ISO</description>
    <arm_group_label>Gelatine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Balanced electrolyte solution</intervention_name>
    <description>Sterofundin ISO</description>
    <arm_group_label>Electrolyte</arm_group_label>
    <arm_group_label>Gelatine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patients ≥ 18 years of age&#xD;
&#xD;
          -  Women of child bearing potential must test negative on standard pregnancy test (urine&#xD;
             or serum)&#xD;
&#xD;
          -  Patients with body weight ≤ 140 kg&#xD;
&#xD;
          -  Patients diagnosed severe sepsis / septic shock at admission on Intensive Care Unit&#xD;
             who can be enrolled within 90 min after admission OR patients diagnosed severe sepsis&#xD;
             / septic shock during Intensive Care Unit stay who can be enrolled within 90 min after&#xD;
             diagnosis&#xD;
&#xD;
          -  Patients where antibiotic therapy has already been started (prior to randomization)&#xD;
&#xD;
          -  Patient who are fluid responsive. Fluid responsiveness is defined as increase of &gt; 10%&#xD;
             in mean arterial pressure (MAP) after passive leg raising (PLR)&#xD;
&#xD;
          -  Signed informed consent by patient, legal representative or authorized person or&#xD;
             deferred consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Administration of HES, dextrane solutions or &gt; 500 ml of Gelatin solutions within the&#xD;
             24 h prior to randomization&#xD;
&#xD;
          -  Death expected within the next 48 h (moribund patients as defined by ASA ≥ class V)&#xD;
&#xD;
          -  Patients for whom the need of pressure infusions are expected&#xD;
&#xD;
          -  Patients with confirmed acute SARS-CoV-2 (COVID-19) infection (as available from&#xD;
             routine medical records/ patient chart)&#xD;
&#xD;
          -  Requirement for renal support (either continuous or discontinuous techniques,&#xD;
             including intermittent haemodialysis, haemofiltration and haemodiafiltration)&#xD;
&#xD;
          -  Patients receiving therapeutic heparin medication due to chronic coagulation disease /&#xD;
             anticoagulation medication (i.e. partial thromboplastin time &gt; 60 sec)&#xD;
&#xD;
          -  Acutely burned patients&#xD;
&#xD;
          -  Contraindications according to summary of product characteristics of investigational&#xD;
             test and reference product&#xD;
&#xD;
          -  Simultaneous participation in another interventional clinical trial (drugs or medical&#xD;
             devices studies)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gernot Marx, Prof. Dr. med.</last_name>
    <role>Study Chair</role>
    <affiliation>Universitätsklinikum Aachen,Klinik für Operative Intensivmedizin</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Manager</last_name>
    <phone>+49-5661-71-0</phone>
    <email>studies@bbraun.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medizinische Universität Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dietmar Fries, Prof. Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fakultní nemocnice Hradec Králové</name>
      <address>
        <city>Hradec Králové</city>
        <zip>50005</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Masarykova nemocnice v Ústí nad Labem, o.z.</name>
      <address>
        <city>Ústí nad Labem</city>
        <zip>401 13</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vladimír Černý, Prof. MUDr., PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Université de Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Pasteur 2 - CHU de Nice</name>
      <address>
        <city>Nice</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Aachen</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gernot Marx, Univ.-Prof. Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Bremen-Mitte</name>
      <address>
        <city>Bremen</city>
        <zip>28177</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rolf Dembinski, Prof. Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Universitätsinstitut - Johannes Wesling Klinikum MInden</name>
      <address>
        <city>Minden</city>
        <zip>32427</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernd Bachmann-Mennenga, Prof. Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Rostock</name>
      <address>
        <city>Rostock</city>
        <zip>18057</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tobias Schuerholz, Prof. Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Szegedi Tudományegyetem - Általános Orvostudományi Kar</name>
      <address>
        <city>Szeged</city>
        <zip>6725</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ricard Ferrer, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuel Sanchez, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Spain</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 17, 2016</study_first_submitted>
  <study_first_submitted_qc>March 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2016</study_first_posted>
  <last_update_submitted>September 24, 2021</last_update_submitted>
  <last_update_submitted_qc>September 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypovolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

